CA2156916A1 - Use of 2-chloro-1¬¬4-(2,6-dichlorophenoxy)methyl|-phenyl|methoxy|- 4-methoxy-benzene for the selective treatment of enteroviral infections in humans - Google Patents

Use of 2-chloro-1¬¬4-(2,6-dichlorophenoxy)methyl|-phenyl|methoxy|- 4-methoxy-benzene for the selective treatment of enteroviral infections in humans

Info

Publication number
CA2156916A1
CA2156916A1 CA002156916A CA2156916A CA2156916A1 CA 2156916 A1 CA2156916 A1 CA 2156916A1 CA 002156916 A CA002156916 A CA 002156916A CA 2156916 A CA2156916 A CA 2156916A CA 2156916 A1 CA2156916 A1 CA 2156916A1
Authority
CA
Canada
Prior art keywords
enteroviral
formula
compound
humans
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002156916A
Other languages
English (en)
French (fr)
Inventor
Edward J. Rozhon
John F. O'connell
Peter Buontempo
Stuart A. Cox
Jason L. Demartino
Jacquelyn M. Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2156916A1 publication Critical patent/CA2156916A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002156916A 1993-02-26 1994-02-23 Use of 2-chloro-1¬¬4-(2,6-dichlorophenoxy)methyl|-phenyl|methoxy|- 4-methoxy-benzene for the selective treatment of enteroviral infections in humans Abandoned CA2156916A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2352793A 1993-02-26 1993-02-26
US08/023,527 1993-02-26

Publications (1)

Publication Number Publication Date
CA2156916A1 true CA2156916A1 (en) 1994-09-01

Family

ID=21815649

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002156916A Abandoned CA2156916A1 (en) 1993-02-26 1994-02-23 Use of 2-chloro-1¬¬4-(2,6-dichlorophenoxy)methyl|-phenyl|methoxy|- 4-methoxy-benzene for the selective treatment of enteroviral infections in humans

Country Status (12)

Country Link
EP (1) EP0686032A1 (cs)
JP (1) JPH08507062A (cs)
AU (1) AU691490B2 (cs)
CA (1) CA2156916A1 (cs)
FI (1) FI953980L (cs)
HU (1) HUT72490A (cs)
IL (1) IL108749A0 (cs)
MX (1) MXPA94001379A (cs)
NZ (1) NZ262794A (cs)
TW (1) TW284686B (cs)
WO (1) WO1994018960A1 (cs)
ZA (1) ZA941244B (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020070390A1 (en) 2018-10-03 2020-04-09 Jyväskylän Yliopisto Vemurafenib and salts thereof for use in the treatment of enteroviral infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8412799U1 (de) * 1984-04-26 1984-10-31 William Prym-Werke Kg, 5190 Stolberg SB-Verkaufsvorrichtung mit einer als Blisterpackung ausgebildeten Verkaufspackung fuer Fadenlegewerkzeuge wie Stricknadeln
CZ279793A3 (en) * 1991-06-19 1994-05-18 Schering Corp Orally active antiviral compounds

Also Published As

Publication number Publication date
FI953980A7 (fi) 1995-08-24
MXPA94001379A (es) 2011-09-26
AU6267994A (en) 1994-09-14
NZ262794A (en) 1997-03-24
HUT72490A (en) 1996-05-28
IL108749A0 (en) 1994-05-30
WO1994018960A1 (en) 1994-09-01
TW284686B (cs) 1996-09-01
AU691490B2 (en) 1998-05-21
EP0686032A1 (en) 1995-12-13
ZA941244B (en) 1994-08-23
FI953980A0 (fi) 1995-08-24
JPH08507062A (ja) 1996-07-30
FI953980L (fi) 1995-08-24
HU9502494D0 (en) 1995-10-30

Similar Documents

Publication Publication Date Title
Pahwa et al. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS
Bearden et al. Enteroviruses in X-linked agammaglobulinemia: update on epidemiology and therapy
Rossignol Nitazoxanide: a first-in-class broad-spectrum antiviral agent
CN103153280B (zh) 丙型肝炎病毒抑制剂的组合
Jackson et al. Management of influenza: use of new antivirals and resistance in perspective
Marker et al. A trial of vidarabine for cytomegalovirus infection in renal transplant patients
Ch'ien et al. Antiviral chemotherapy and neonatal herpes simplex virus infection: a pilot study—experience with adenine arabinoside (ARA-A)
EP2585067B1 (en) Compound for the treatment of enteroviruses
WO2003050129A1 (en) Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
Wang et al. In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean–Congo hemorrhagic fever virus
Kawashima et al. A phase 3, randomized, double‐blind, placebo‐controlled study evaluating a single, patient‐initiated dose of amenamevir for recurrent herpes labialis
CA2156916A1 (en) Use of 2-chloro-1¬¬4-(2,6-dichlorophenoxy)methyl|-phenyl|methoxy|- 4-methoxy-benzene for the selective treatment of enteroviral infections in humans
Al-juhaishi et al. Safety and Efficacy of antiviral drugs against covid-19 infection: an updated systemic review
US5519028A (en) Antiviral preparations
CN113332279A (zh) Ganetespib化合物在制备抗EV71病毒药物中的应用
Kroon et al. Long-term suppression of severe recurrent genital herpes simplex infections with oral acyclovir: a dose-titration study.
Mtewa et al. Drug repurposing for SARS-CoV-2 (COVID-19) treatment
Mellette et al. Toxic reaction to para-aminosalicylic acid and isoniazid accompanied by leukopenia and atypical lymphocytosis
Togo et al. Antiviral effect of 3, 4-dihydro-1-isoquinolineacetamide hydrochloride in experimental human rhinovirus infection
Longson The treatment of herpes encephalitis
US20230213515A1 (en) Drug and diagnostic combination system to identify and treat single-stranded rna viruses including coronaviruses and monkeypox
CN102335171A (zh) 一类n-(2-噻唑)苯甲酰胺衍生物的应用
Talsma et al. Generalised Coxsackie A9 infection in a neonate presenting with pericarditis.
Wunderli et al. Outer retinal necrosis due to a strain of varicella-zoster virus resistant to acyclovir, ganciclovir, and sorivudine
US20220409583A1 (en) Treatment and Prevention of Dengue Disease

Legal Events

Date Code Title Description
FZDE Discontinued